Back to Search
Start Over
Neuroimaging features of cognitive impairments in schizophrenia and major depressive disorder.
- Source :
-
Therapeutic advances in psychopharmacology [Ther Adv Psychopharmacol] 2024 May 04; Vol. 14, pp. 20451253241243290. Date of Electronic Publication: 2024 May 04 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Cognitive dysfunctions are one of the key symptoms of schizophrenia (SZ) and major depressive disorder (MDD), which exist not only during the onset of diseases but also before the onset, even after the remission of psychiatric symptoms. With the development of neuroimaging techniques, these non-invasive approaches provide valuable insights into the underlying pathogenesis of psychiatric disorders and information of cognitive remediation interventions. This review synthesizes existing neuroimaging studies to examine domains of cognitive impairment, particularly processing speed, memory, attention, and executive function in SZ and MDD patients. First, white matter (WM) abnormalities are observed in processing speed deficits in both SZ and MDD, with distinct neuroimaging findings highlighting WM connectivity abnormalities in SZ and WM hyperintensity caused by small vessel disease in MDD. Additionally, the abnormal functions of prefrontal cortex and medial temporal lobe are found in both SZ and MDD patients during various memory tasks, while aberrant amygdala activity potentially contributes to a preference to negative memories in MDD. Furthermore, impaired large-scale networks including frontoparietal network, dorsal attention network, and ventral attention network are related to attention deficits, both in SZ and MDD patients. Finally, abnormal activity and volume of the dorsolateral prefrontal cortex (DLPFC) and abnormal functional connections between the DLPFC and the cerebellum are associated with executive dysfunction in both SZ and MDD. Despite these insights, longitudinal neuroimaging studies are lacking, impeding a comprehensive understanding of cognitive changes and the development of early intervention strategies for SZ and MDD. Addressing this gap is critical for advancing our knowledge and improving patient prognosis.<br />Competing Interests: The authors declare that there is no conflict of interest.<br /> (© The Author(s), 2024.)
Details
- Language :
- English
- ISSN :
- 2045-1253
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Therapeutic advances in psychopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 38708374
- Full Text :
- https://doi.org/10.1177/20451253241243290